Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye

British Journal of Ophthalmology

Volumn 96, Issue 12, 2012, Pages 1498-1503

  Liew, Melissa ^a   Zhang, Min ^a   Kim, Elizabeth ^a   Akpek, Esen K ^b  

^a PFIZER INC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; RHEUMATOID FACTOR; SJOEGREN SPECIFIC ANTIBODY A; SJOEGREN SPECIFIC ANTIBODY B; UNCLASSIFIED DRUG;

ADULT; AQUEOUS DEFICIENT DRY EYE; ARTICLE; COHORT ANALYSIS; CONJUNCTIVAL LISSAMINE GREEN STAINING; CORNEAL FLUORESCEIN STAINING; DRY EYE; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OCULAR SURFACE DISEASE INDEX; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIRMER TEST; SJOEGREN SYNDROME; STAINING; TEAR FILM BREAKUP TIME; CHEMISTRY; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; IMMUNOLOGY; LACRIMAL FLUID; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, ANTINUCLEAR; CONJUNCTIVA; CORNEA; DIAGNOSIS, DIFFERENTIAL; DRY EYE SYNDROMES; FOLLOW-UP STUDIES; HUMANS; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TEARS;

EID: 84869874313     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-301767     Document Type: Article

References (24)

1. Akpek EK, Klimava A, Thorne JE, et al. Evaluation of patients with dry eye for presence of underlying Sjogren syndrome. Cornea 2009;28:493-7.
2. International Dry Eye Workshop. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92.
3. International Dry Eye Workshop. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:179-93.
4. Miljanovic B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007;143:409-15.
5. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
6. Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004;33:39-43.
7. Thomas E, Hay EM, Hajeer A, et al. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998;37:1069-76.
8. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010;9:A305-10.
9. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164:1275-84.
10. Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002;81:270-80.
11. Segal B, Bowman SJ, Fox PC, et al. Primary Sjogren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009;7:46.
12. Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93.
13. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7.
14. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
15. Liew MSH, Nicholls K, Klamerus K, et al. Safety and efficacy of topical ophthalmic CP-690,550, a Janus kinase inhibitor, for dry eye disease: a Phase 1/2 clinical trial. Presented at Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, Fort Lauderdale, FL, USA, May 1-5, 2011.
16. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest Ophthalmol Vis Sci 2002;43:2609-14.
17. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995;21:221-32.
18. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-50.
19. Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 2010;149:405-15.
20. Caffery B, Simpson T, Wang S, et al. Rose Bengal staining of the temporal conjunctiva differentiates Sjogren's syndrome from keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2010;51:2381-7.
21. Yuan Y, Wang J, Chen Q, et al. Reduced tear meniscus dynamics in dry eye patients with aqueous tear deficiency. Am J Ophthalmol 2010;149:932-8.
22. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11.
23. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. Autoimmun Rev 2010;10:123-5.
24. Huo AP, Lin KC, Chou CT. Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjogren's syndrome. Int J Rheum Dis 2010;13:39-47.